| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1ebc036a7e126f539f52eddfbdaf577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4fcb1f0ba17518daed668e86447176
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75d5ad329cb5f221f09c783e0329d86d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c8093e9253eafa6c438998ea0980b34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c00af9240b6e7e94dd443884ff82251d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e6042074bf572d642aab5df1f296ec0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6898
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1997-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c79e0fa6e9e1bdc20865232b0e05d3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_174245ddb97958a3d513e32c9b69c36f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_417b2df6c0b254ca75ad3c1694636533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06f053f2d4933f62778bf51a332a89fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_743dfad97d5808ca678363415f9d2451 |
| publicationDate |
1997-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9731655-A3 |
| titleOfInvention |
Modified cytokines for therapeutic use |
| abstract |
The object of the present invention is a new method and new products for the therapeutic use of cytokines. The method is based on the sequential administration of a component A (e.g. a biotinylated antibody) able to deliver onto a particular pathologic target a second component B (e.g. avidin), followed by a component able to bind the component B (component C) (e.g. biotin), conjugated with the cytokines. The method permits to increase the local concentration of the modified cytokines (C-cytokines) through the interaction with the 'artificial' receptor B and to cause a local biologic response mediated by 'natural' receptors. |
| priorityDate |
1996-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |